Three New Drug Programs Enter Human Clinical Trials
The San Francisco-based TCG Labs Soleil has launched Phase 1 testing for candidates targeting cancer and clotting disorders.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
Three drug candidates developed by TCG Labs Soleil have officially moved into their first round of human clinical trials. The San Francisco-based biotech hub launched these programs as part of its expanding portfolio of companies.
Why it matters
These Phase 1 trials are a crucial early test to see if new drugs for solid tumors, prostate cancer, and blood clotting disorders are safe for humans to take. The progress represents a significant step for the local biotech hub, which has scaled to 19 companies since its 2024 founding.
TCG Labs Soleil has built 19 portfolio companies since its 2024 launch, with three now undergoing Phase 1 clinical trials for various conditions. Results on safety and tolerability for these treatments remain pending.
The players
TCG Labs Soleil
A San Francisco-based biotech R&D hub that builds and operates independent portfolio companies to advance medical therapies.
Duboce Biopharmaceuticals
A TCG Labs Soleil portfolio company currently testing the drug DBC-664 for solid tumors.
Juri Biosciences
A TCG Labs Soleil portfolio company evaluating JUR-003 for metastatic prostate cancer.
Arguello Biosciences
A TCG Labs Soleil portfolio company testing the drug ARG-397 for thromboembolic disorders.
Clement Therapeutics
A TCG Labs Soleil portfolio company developing the CMT-133 antibody for inflammatory respiratory diseases.
The details
The trials focus on safety and pharmacokinetics for three drugs: Duboce Biopharmaceuticals is testing DBC-664 for solid tumors, Juri Biosciences is studying JUR-003 for prostate cancer, and Arguello Biosciences is evaluating ARG-397 for thromboembolic disorders. Meanwhile, Clement Therapeutics has finished the initial studies required to advance its CMT-133 antibody for respiratory disease. The lab intends to begin human trials for the respiratory drug before the end of the year.
Timeline
2024: TCG Labs Soleil launched its in-house R&D hub.
October 28, 2026: The company announced the initiation of clinical trials for three drug programs.
Remaining 2026: Clement Therapeutics plans to start its first-in-human trial for CMT-133.
2026: European Respiratory Society Congress.
Across the Bay
The transition of three internal programs into human trials follows the growth trajectory of the TCG Labs Soleil hub established in 2024. This milestone marks the first time the local incubator has pushed multiple therapeutic candidates from R&D into clinical testing simultaneously.
These clinical trials represent the movement of local research from the lab bench to initial human testing. While the trials themselves do not change daily routines, they represent the ongoing development of potential new treatments emerging from the city's biotech sector.
The takeaway
These trials represent a critical early checkpoint for new cancer and clotting therapies developed in San Francisco. Keep an eye on the company's announcements for the planned CMT-133 trial launch before the end of the year.
What happens next
Clement Therapeutics is scheduled to initiate its first-in-human clinical trial for the antibody CMT-133 by the end of 2026.
Further reading
For more news on local life sciences, visit Biotech.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
